OHSU Knight Cancer Institute Research Groups:OCI Research Group Meetings

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
m (Schedule)
(Schedule)
(38 intermediate revisions not shown.)
Line 44: Line 44:
[http://omlc.ogi.edu Jacques Lab], Biomedical Engineering/Dermatology
[http://omlc.ogi.edu Jacques Lab], Biomedical Engineering/Dermatology
 +
[http://www.ohsu.edu/xd/education/schools/school-of-medicine/departments/basic-science-departments/biomedical-engineering/people/joe-gray.cfm Gray Lab], OHSU Center for Spacial Systems Biology
*Add your lab here
*Add your lab here
Line 61: Line 62:
| 9/21/2012
| 9/21/2012
| Rebecca Block <blockr@ohsu.edu>
| Rebecca Block <blockr@ohsu.edu>
-
|   
+
“Symptoms of Depression among Adolescent and Young Adult Latino Men with Cancer”
-
|
+
|  
|  
 +
|Mac Hall 2201
|--
|--
| <font color=red>9/28/2012</font>  
| <font color=red>9/28/2012</font>  
Line 69: Line 70:
|Hematologic Malignancies - Guang Fan, "Highlights of translational research for Hematologic malignancy in Hemepath division"
|Hematologic Malignancies - Guang Fan, "Highlights of translational research for Hematologic malignancy in Hemepath division"
Carol Beading, “Ion Torrent technology for AML/MDS mutation testing"   
Carol Beading, “Ion Torrent technology for AML/MDS mutation testing"   
-
|
+
|
|Mac Hall 2201  
|Mac Hall 2201  
|--
|--
|10/5/2012
|10/5/2012
|Larry Sherman
|Larry Sherman
-
|
+
|Mechanisms underlying cognitive disturbances in patients undergoing cancer chemotherapy: A possible intervention
|
|
|Mac Hall 2201   
|Mac Hall 2201   
Line 82: Line 83:
|Hematologic Malignancies
|Hematologic Malignancies
|  
|  
-
|
 
|Mac Hall 2201   
|Mac Hall 2201   
|--
|--
|10/19/2012
|10/19/2012
-
|Wei Huang <huangwe@ohsu.edu>
+
|Wei Huang  
-
|
+
|Quantitative DCE-MRI as a predictor of therapeutic response in acute leukemia
|  
|  
|Mac Hall 2201  
|Mac Hall 2201  
|--
|--
| <font color=red>10/26/2012</font>  
| <font color=red>10/26/2012</font>  
-
|
+
|Jeffrey Tyner/Marc Loriaux
-
|Hematologic Malignancies -  
+
|Hematologic Malignancies - Jeffrey Tyner: Functional Genomics on Primary Leukemia Specimens to Identify Novel Driver Oncogenes and Therapeutic Strategies
|  
|  
|Mac Hall 2201  
|Mac Hall 2201  
Line 99: Line 99:
|11/2/2012
|11/2/2012
| Jim Korkola
| Jim Korkola
-
|  
+
|
 +
|Mac Hall 2201
|Mac Hall 2201
|--
|--
|11/9/2012
|11/9/2012
-
| Knight Cancer Institute Retreat
+
| CANCEL - KNIGHT RESEARCH RETREAT
-
|  
+
|
-
|Mac Hall 2201
+
|
 +
|Skamania Lodge
|--
|--
| 11/16/2012  
| 11/16/2012  
|Owen McCarty
|Owen McCarty
 +
|Development of coagulation factor probes for the identification of procoagulant cancer cells
|  
|  
|Mac Hall 2201  
|Mac Hall 2201  
|--
|--
-
|11/26/2012
+
|11/23/2012
| CANCEL - THANKSGIVING
| CANCEL - THANKSGIVING
|  
|  
 +
|
|
|
|--
|--
Line 125: Line 129:
|12/7/2012  
|12/7/2012  
|Thayer Lab   
|Thayer Lab   
 +
|cis-acting elements that control chromosome-wide replication and stability
|  
|  
|Mac Hall 2201  
|Mac Hall 2201  
|--
|--
|<font color=red>12/14/2012</font>  
|<font color=red>12/14/2012</font>  
 +
|William Hersh, MD <br>
 +
Professor and Chair<br>
 +
Department of Medical Informatics & Clinical Epidemiology<br>
 +
hersh@ohsu.edu<br>
 +
|Opportunities for Collaboration Between Biomedical Informatics and Basic, Clinical, and Translational Sciences
|
|
-
|Hematologic Malignancies -
 
-
|
 
|Mac Hall 2201  
|Mac Hall 2201  
|--
|--
|12/21/2012  
|12/21/2012  
|Charles Keller
|Charles Keller
-
|  
+
|Talk 1:  leptomeningeal metastastis as a cytokine-mediated process;
 +
Talk 2:  Status of the Pediatric Cancer Biology Program
 +
|Mac Hall 2201  
|Mac Hall 2201  
|--
|--
| <font color=red>1/4/2013</font>  
| <font color=red>1/4/2013</font>  
-
|Hematologic Malignancies
+
|Hematologic Malignancies  
-
|  
+
|No Meeting
 +
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
|1/11/2013
+
|<font color=red>1/11/2013</font>  
-
|Diane Elliot <elliotd@ohsu.edu>
+
|Hematologic Malignancies
-
|
+
|Angela Fleischman
 +
Title: Inflammation as a driver of clonal evolution in myeloproliferative neoplasms.
|  
|  
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
| <font color=red>1/18/2013</font>  
+
|1/18/2012
-
|Hematologic Malignancies -
+
|Diane Elliot <elliotd@ohsu.edu>  
|
|
|  
|  
Line 158: Line 170:
|1/25/2013
|1/25/2013
|Zhi and Wassana
|Zhi and Wassana
 +
|
|  
|  
|Mac Hall 2201  
|Mac Hall 2201  
|--
|--
| <font color=red>2/1/2013</font>  
| <font color=red>2/1/2013</font>  
-
|  
+
| canceled
|
|
|  
|  
Line 168: Line 181:
|--
|--
|2/8/2013
|2/8/2013
-
|
+
|canceled
|
|
|  
|  
Line 176: Line 189:
|
|
|
|
 +
|
|Mac Hall 2201
|Mac Hall 2201
|--
|--
|2/22/2013
|2/22/2013
-
|
+
|Eric Orwoll/Katrina Goddard
-
|  
+
|Eric Orwoll <br>
 +
Evolving the OHSU-wide clinical/translational research infrastructure<br>
 +
Katrina Goddard <br>
 +
NW Biobank at Kaiser NW, a source of serum/plasma, DNA, and tissue all linked to electronic medical records
 +
|Mac Hall 2201
|Mac Hall 2201
|--
|--
Line 190: Line 208:
|--
|--
|3/8/2013
|3/8/2013
-
|  
+
| Tania Vu
-
|  
+
|"Quantum Dot Technology for Functional Assessment of Phosphokinase Signaling in Cancer"
 +
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
| 3/15/2013
+
| <font color=red>3/15/2013</font>
|
|
|  
|  
Line 200: Line 219:
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
|<font color=red>3/22/2013</font>
+
|3/22/2013
 +
 +
|
|   
|   
-
|
 
|Mac Hall 2201
|Mac Hall 2201
|--
|--
Line 209: Line 229:
|
|
|
|
-
|Mac Hall 2201
+
|  
|--
|--
-
| <font color=red>4/5/2013</font>
+
|4/5/2013
-
|  
+
| Mitchell Turker
-
|  
+
|Chromosome loss, tetraploidy, and aneuploidy
|
|
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
|4/12/2012
+
|<font color=red>4/12/2013</font>
|  
|  
|
|
Line 223: Line 243:
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
| <font color=red>4/19/2013</font>
+
| 4/19/2013
|
|
|
|
 +
|
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
|4/26/2013
+
|<font color=red>4/26/2013</font>
|
|
|
|
Line 234: Line 255:
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
| <font color=red>5/3/2013</font>
+
| 5/3/2013
|  
|  
|
|
 +
|
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
| 5/10/2013
+
| <font color=red>5/10/2013</font>
|
|
|
|
 +
|
|Mac Hall 2201  
|Mac Hall 2201  
|--
|--
-
|<font color=red>5/17/2013</font>
+
|5/17/2013
 +
|
|
|
|
|
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
|5/24/2013
+
|<font color=red>5/24/2013</font>
|
|
|
|
Line 255: Line 279:
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
|<font color=red>5/31/2013</font>
+
|5/31/2013
|
|
|
|
Line 261: Line 285:
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
|6/7/2013
+
|<font color=red>6/7/2013</font>
|
|
|
|
Line 267: Line 291:
|Mac Hall 2201
|Mac Hall 2201
|--
|--
-
|<font color=red>6/14/2013</font>
+
|6/14/2013
|
|
|
|
|  
|  
|Mac Hall 2201
|Mac Hall 2201

Revision as of 13:16, 29 January 2013

Equipped with his five senses, man explores the universe around him and calls the adventure Science.  ~Edwin Powell Hubble, The Nature of Science, 1954

Home        Faculty        Graduate Program        Postdocs        OHSU Knight Core Facilities       



Programs     Res Group Meetings        Cancer Journal Club        Cell/CANB 616        Gen. Inst/R3 Club     CANB 610    


Contents

Objectives of the OHSU Knight Cancer Biology Research Group Meetings

Cross-departmental workshop composed of students, postdocs, and faculty with shared interest in basic principles and emerging discoveries in Cancer Biology. The goals of the meetings and this wiki:

  • Establish a challenging and interactive cross-departmental focus group that will advance understanding of our individual projects and encourage collaborations.
  • Provide students and postdocs with training and interactions with faculty interested in Cancer Biology and emerging therapeutics

These meetings are now expanded to include a Translational Cancer Research Group Meeting. The purpose of this meeting is to:

  • Serve to foster a Knight translational research incubator for projects and teams leading to multi-investigator cancer program/SPORE funding including the Solid tumors and Hematologic Malignancies programs and the Systems Biology group.
  • Meetings will include thematic research and clinical research talks with collaborative and developmental potential and Brainstorming Sessions.

Knight Research Group Activities

Want to join us? All are invited!

To get on the listserve:
go to the following web site:
http://mailman.ohsu.edu/cgi-bin/mailman/listinfo/oncres
follow the instructions for subscribing
  • We meet in Mac Hall 2201
Fridays 9:00-10:15 AM - see schedule below
Breakfast provided by the Knight!
  • Organizer: Rosie Sears, email searsrATohsu.edu

Member Labs and Affiliations

Lopez Lab Hem Onc

Sears Lab, MMG

Hoatlin Lab, BMB

Thayer Lab, BMB

Lloyd Lab, CROET

McCullough Lab, CROET

Wong Lab, Dermatology, CDB

Zundel Lab, Radiation Medicine, Cancer Biology

Spindel Lab, Primate Center, NGP, Cancer Biology

Jacques Lab, Biomedical Engineering/Dermatology

Gray Lab, OHSU Center for Spacial Systems Biology

  • Add your lab here

Schedule

*Red indicates Translational Cancer Research Group Meetings

Date Presenters Topic Links & Comments Location
9/21/2012 Rebecca Block <blockr@ohsu.edu> “Symptoms of Depression among Adolescent and Young Adult Latino Men with Cancer” Mac Hall 2201
9/28/2012 Guang Fan Hematologic Malignancies - Guang Fan, "Highlights of translational research for Hematologic malignancy in Hemepath division"

Carol Beading, “Ion Torrent technology for AML/MDS mutation testing"

Mac Hall 2201
10/5/2012 Larry Sherman Mechanisms underlying cognitive disturbances in patients undergoing cancer chemotherapy: A possible intervention Mac Hall 2201
10/12/2012 Tibor Kovacsovics/William Harv Fleming Hematologic Malignancies Mac Hall 2201
10/19/2012 Wei Huang Quantitative DCE-MRI as a predictor of therapeutic response in acute leukemia Mac Hall 2201
10/26/2012 Jeffrey Tyner/Marc Loriaux Hematologic Malignancies - Jeffrey Tyner: Functional Genomics on Primary Leukemia Specimens to Identify Novel Driver Oncogenes and Therapeutic Strategies Mac Hall 2201
11/2/2012 Jim Korkola Mac Hall 2201
11/9/2012 CANCEL - KNIGHT RESEARCH RETREAT Skamania Lodge
11/16/2012 Owen McCarty Development of coagulation factor probes for the identification of procoagulant cancer cells Mac Hall 2201
11/23/2012 CANCEL - THANKSGIVING
11/30/2012 Brandon Hayes-Lattin/Rebecca Block Hematologic Malignancies Mac Hall 2201
12/7/2012 Thayer Lab cis-acting elements that control chromosome-wide replication and stability Mac Hall 2201
12/14/2012 William Hersh, MD

Professor and Chair
Department of Medical Informatics & Clinical Epidemiology
hersh@ohsu.edu

Opportunities for Collaboration Between Biomedical Informatics and Basic, Clinical, and Translational Sciences Mac Hall 2201
12/21/2012 Charles Keller Talk 1: leptomeningeal metastastis as a cytokine-mediated process;

Talk 2: Status of the Pediatric Cancer Biology Program

Mac Hall 2201
1/4/2013 Hematologic Malignancies No Meeting Mac Hall 2201
1/11/2013 Hematologic Malignancies Angela Fleischman

Title: Inflammation as a driver of clonal evolution in myeloproliferative neoplasms.

Mac Hall 2201
1/18/2012 Diane Elliot <elliotd@ohsu.edu> Mac Hall 2201
1/25/2013 Zhi and Wassana Mac Hall 2201
2/1/2013 canceled Mac Hall 2201
2/8/2013 canceled Mac Hall 2201
2/15/2013 Mac Hall 2201
2/22/2013 Eric Orwoll/Katrina Goddard Eric Orwoll

Evolving the OHSU-wide clinical/translational research infrastructure
Katrina Goddard
NW Biobank at Kaiser NW, a source of serum/plasma, DNA, and tissue all linked to electronic medical records

Mac Hall 2201
3/1/2013 Mac Hall 2201
3/8/2013 Tania Vu "Quantum Dot Technology for Functional Assessment of Phosphokinase Signaling in Cancer" Mac Hall 2201
3/15/2013 Mac Hall 2201
3/22/2013 Mac Hall 2201
3/29/2013 CANCEL - SPRING BREAK
4/5/2013 Mitchell Turker Chromosome loss, tetraploidy, and aneuploidy Mac Hall 2201
4/12/2013 Mac Hall 2201
4/19/2013 Mac Hall 2201
4/26/2013 Mac Hall 2201
5/3/2013 Mac Hall 2201
5/10/2013 Mac Hall 2201
5/17/2013 Mac Hall 2201
5/24/2013 Mac Hall 2201
5/31/2013 Mac Hall 2201
6/7/2013 Mac Hall 2201
6/14/2013 Mac Hall 2201